Truist Securities Cuts Price Target on Pediatrix Medical to $8 From $10, Maintains Hold Rating
Pediatrix Medical Group Analyst Ratings
Truist Securities Maintains Hold on Pediatrix Medical Group, Lowers Price Target to $8
Pediatrix Medical Group Analyst Ratings
Deutsche Bank Upgrades Pediatrix Medical Group to Hold From Sell, $8 Price Target
Pediatrix Medical Group Analyst Ratings
Maintaining Hold: Assessing Pediatrix Medical Group's Rebound Amidst Restructuring and Rising Costs
Pediatrix Medical Group: Hold Rating Amidst Positive Birth Trends and Revenue Cycle Risks
Maintaining Hold on Pediatrix Medical Group Amidst Birth Rate Trends and Financial Caution
Pediatrix Medical Group Analyst Ratings
Maintaining Hold on Pediatrix Medical Group Amidst Cost Challenges and Earnings Growth Uncertainty
Truist Securities Adjusts Price Target on Pediatrix Medical Group to $10 From $10.50, Keeps Hold Rating
Pediatrix Medical Group Analyst Ratings
Pediatrix Medical Group: Hold Rating Amidst Declining Birth Rates and Cost Inflation Concerns
Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT), Regeneron (REGN) and Pediatrix Medical Group (MD)
Hold Rating on Pediatrix Medical Group Amidst Challenging Financial Outlook and Cost Inflation Concerns
Maintaining Hold on Pediatrix Medical Group Amidst Subdued Birth Rate Growth and Persistent Cost Challenges
UBS Initiates Coverage On Pediatrix Medical Group With Neutral Rating, Announces Price Target of $9.5
Pediatrix Medical Group Analyst Ratings
Hold Rating on Pediatrix Medical Group Amid Operational Costs and Revenue Struggles: An Analysis by Whit Mayo of Leerink Partners